These results have motivated recent administration of ASOs targeting ATXN2 to human patients with ALS with or without polyQ expansions in a phase 1 clinical trial (ClinicalTrials.gov: NCT04494256). This evidence concerns the gene ATXN2 and amyotrophic lateral sclerosis.